Optimising the Patient Journey in Chronic Spontaneous Urticaria

Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23rd EADV Congress, Amsterdam, the Netherlands, on 9th October 2014

Chairperson: Marcus Maurer1
Speakers: Clive Grattan,2 Donald E Stull,3 Ana Giménez-Arnau4

1. Charité – Universitätsmedizin Berlin, Germany
2. Norfolk & Norwich University NHS Foundation Trust, Norwich; St John’s Institute of Dermatology, London, UK
3. Data Analytics and Design Strategy, RTI Health Solutions, Manchester, UK
4. Hospital del Mar, Parc de Salut Mar, Universitat Autonoma, Barcelona, Spain

Disclosure: Prof Maurer has received research funding and/or honoraria for consulting/lectures from Almirall, Essex Pharma, Genentech, JADO Technologies, Merckle Recordati, Moxie, Novartis, Sanofi Aventis, Schering-Plough, Merck, MSD, UCB, and Uriach. Dr Grattan has consultancies with GSK, Genentech, Novartis, and CSL Behring. Dr Stull is employed by RTI Health Solutions, which provides consulting and other research services to pharmaceutical, device, government, and non-government organisations. As an employee of RTI-HS, Dr Stull works with a variety of companies and organisations. No payment or honoraria are received directly from these organisations for services rendered. Prof Giménez-Arnau is a Medical Advisor for Uriach Pharma, Genentech, and Novartis; has received research grants supported by Intendis – Bayer, Uriach Pharma, and Novartis; and has educational activities sponsored by Uriach Pharma, Novartis, Genentech, Menarini, GSK, MSD, and Almirall.
Acknowledgements: Writing assistance provided by Dr Saroshi Amirthalingam, Apothecom Scopemedical Ltd.
Support: The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily of Novartis.
Citation: EMJ Dermatol. 2014;2:35-40.

Meeting Summary

Prof Marcus Maurer opened the symposium with an introduction to chronic urticaria (CU), as well as its two subtypes (chronic spontaneous urticaria [CSU] and chronic inducible urticaria [CIndU]), and the currently available therapeutic strategies. Dr Clive Grattan spoke about the burden of disease in patients with CSU and the specific effects it has on a patient’s quality of life as well as the socioeconomic impact. Dr Donald Stull explained the importance of measuring the impact of disease using patient reported outcomes. Prof Ana Giménez-Arnau concluded the symposium by presenting the latest data on omalizumab for refractory CSU while touching on the recommendations in the latest urticaria guidelines. Interactive keypads were available throughout the symposium which allowed delegates to vote on different questions about their experience in treating patients with urticaria, posed by the speakers.


Introduction from the Chair
Burden of Disease and Unmet Needs in Patients with Refractory CSU
CSU from a Patient Perspective – What can we Learn?
Omalizumab and the Latest Data for Refractory CSU
Panel Discussion/Audience Q&A

Download (PDF, 158KB)

Comments are closed.